← MapLight Therapeutics, Inc. (MPLT) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
MapLight Therapeutics, Inc. (MPLT)
Pharmaceutical Preparations · market cap $469M · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-15 (est.)
Phase 2
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
MapLight Therapeutics (MPLT) is a clinical-stage pharmaceutical company with 114 employees and a $1.6B market cap, focused on CNS disorders. Its lead asset ML-007C-MA is in Phase 2 for Psychosis Associated with Alzheimer's Disease and is also being evaluated in Schizophrenia BID; a second asset, ML-004, is in Phase 2 for Autism Spectrum Disorder, with data expected October 2025. The company carries $395M in cash (~23 months runway) and no revenue, burning approximately $138M annually in R&D.
The catalyst path
- 2026-10-15 (est.)Phase 2 · ML-004 (IR)/(ER) tabletimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ML-007C-MA | Phase 2 | Psychosis Associated With Alzheimer's Disease |
| ML-004 (IR)/(ER) tablet | Phase 2 | Autism Spectrum Disorder |
| ML-007C-MA BID | Phase 2 | Schizophrenia |
Price & technical context
3-month
-71.8%
6-month
-49.9%
12-month
—
52-wk range
$9.90–$39.80
vs 50-day MA
-24.8%
vs 200-day MA
-52.9%
Realized vol
159.8%
Max drawdown
-75.1%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MPLT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.